A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Exclusion criteria

• ✕. Has other malignant tumors within 3 years;
• ✕. Has multiple factors affecting oral medication;
• ✕. Unalleviated toxicity ≥ grade 1 due to any previous anticancer therapy;
• ✕. Has active or uncontrolled severe infections before the first dose;
• ✕. Cirrhosis, active hepatitis#
• ✕. Have a history of immunodeficiency; 2. Tumor-related symptoms and treatment:
• ✕. Has central nervous system metastases (CNS) and/or cancerous meningitis or leptomeningeal carcinomatosis;
• ✕. Had received chemotherapy within 3 weeks prior to the first dose, and had received radiotherapy , hormone therapy, or other anti-tumor therapy within 2 weeks prior to the first dose;